Study Information

This page contains answers to frequently asked questions.

BADBIR FAQ

What is BADBIR?

BADBIR stands for the British Association of Dermatologists Biologic and Immunomodulators Register. We are a UK and Eire observational study seeking to assess the long-term safety of biologic treatments for psoriasis. The National Institute for Health and Clinical Excellence (NICE) has recommended that all patients in the UK receiving these new therapies for psoriasis should be registered with us. Once a patient has joined BADBIR, they are followed up via their dermatologist as we assess their clinical details.

How is the study progressing?

There are currently over 160 hospital sites across the UK and Eire taking part in BADBIR by recruiting participants to join the Register. We have over 18,000 registrations in the study, with more than 110,000 follow-ups entered. BADBIR was 10 years old in 2017!

There are already some research publications from the BADBIR data - visit our Publications page for the details.

Q3: When is the study end date?

BADBIR has ethical approval to continuing following participants to 31st July 2028.

Q4: Can my hospital register with BADBIR?

We're still open for new centres to register with us to begin recruiting participants. If your hospital is not yet approved, please contact the BADBIR office and we'll be able to advise you on the steps that need to be taken.

If your centre is already participating on the BADBIR study, you can register for a database account to access your centre's data.

Q5: Who is in charge of the direction of BADBIR?

BADBIR is guided and supervised by a Steering Committee. The Committee is facilitated by the British Association of Dermatologists and meets three times annually (typically February, June and October).